Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   37504   clinical trials with a EudraCT protocol, of which   6153   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Phase 1, Randomized, Open-label Study to Evaluate the Relative Bioavailability, Food Effect, and Dose Proportionality of a Granule Formulation of Lumacaftor in Combination With Ivacaftor in Healthy Adult Subjects

    Summary
    EudraCT number
    2019-002254-23
    Trial protocol
    Outside EU/EEA  
    Global end of trial date
    01 Dec 2015

    Results information
    Results version number
    v1(current)
    This version publication date
    04 Oct 2019
    First version publication date
    04 Oct 2019
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    VX15-809-014
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    -
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Vertex Pharmaceuticals Incorporated
    Sponsor organisation address
    50 Northern Avenue, Boston, Massachusetts, United States,
    Public contact
    Medical Monitor, Vertex Pharmaceuticals Incorporated, +1 617 341 6777, medicalinfo@vrtx.com
    Scientific contact
    Medical Monitor, Vertex Pharmaceuticals Incorporated, +1 617 341 6777, medicalinfo@vrtx.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    Yes
    EMA paediatric investigation plan number(s)
    EMEA-001582-PIP01-13
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    26 Feb 2016
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    24 Nov 2015
    Global end of trial reached?
    Yes
    Global end of trial date
    01 Dec 2015
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    To evaluate the relative bioavailability of the granule formulation compared to the tablet formulation of lumacaftor (LUM)/ivacaftor (IVA)
    Protection of trial subjects
    The study was conducted in accordance with the ethical principles stated in the Declaration of Helsinki and the International Council on Harmonization (ICH) Guideline for Good Clinical Practice (GCP).
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    22 Sep 2015
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    United States: 16
    Worldwide total number of subjects
    16
    EEA total number of subjects
    0
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    16
    From 65 to 84 years
    0
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    -

    Pre-assignment
    Screening details
    A total of 16 subjects were enrolled and randomized in the study.

    Period 1
    Period 1 title
    Overall Period
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Sequence 1
    Arm description
    Subjects received LUM/IVA Dose 1 tablet formulation in fed state in treatment period 1, then LUM/IVA Dose 1 granule formulation in fasted state in treatment period 2, then LUM/IVA Dose 1 granule formulation in fed state in treatment period 3, and then LUM/IVA Dose 2 granule formulation in fed state in treatment period 4. A washout period of at least 10 days occurred between each dosing occasion.
    Arm type
    Experimental

    Investigational medicinal product name
    LUM/IVA
    Investigational medicinal product code
    VX-809/ VX-770
    Other name
    Lumacaftor/Ivacaftor fixed dose combination
    Pharmaceutical forms
    Tablet, Granules
    Routes of administration
    Oral use
    Dosage and administration details
    Subjects received a single dose of LUM/IVA tablet or granule formulation in the fed or fasted state on Day 1 in treatment period 1, 2, 3 and 4 as per the sequence.

    Arm title
    Sequence 2
    Arm description
    Subjects received LUM/IVA Dose 1 granule formulation in fed state in treatment period 1, then LUM/IVA Dose 1 tablet formulation in fed state in treatment period 2, then LUM/IVA Dose 2 granule formulation in fed state in treatment period 3, and then LUM/IVA Dose 1 granule formulation in fasted state in treatment period 4. A washout period of at least 10 days occurred between each dosing occasion.
    Arm type
    Experimental

    Investigational medicinal product name
    LUM/IVA
    Investigational medicinal product code
    VX-809/ VX-770
    Other name
    Lumacaftor/Ivacaftor fixed dose combination
    Pharmaceutical forms
    Granules, Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Subjects received a single dose of LUM/IVA tablet or granule formulation in the fed or fasted state on Day 1 in treatment period 1, 2, 3 and 4 as per the sequence.

    Arm title
    Sequence 3
    Arm description
    Subjects received LUM/IVA Dose 2 granule formulation in fed state in treatment period 1, then LUM/IVA Dose 1 granule formulation in fed state in treatment period 2, then LUM/IVA Dose 1 granule formulation in fasted state in treatment period 3, and then LUM/IVA Dose 1 tablet formulation in fed state in treatment period 4. A washout period of at least 10 days occurred between each dosing occasion.
    Arm type
    Experimental

    Investigational medicinal product name
    LUM/IVA
    Investigational medicinal product code
    VX-809/ VX-770
    Other name
    Lumacaftor/Ivacaftor fixed dose combination
    Pharmaceutical forms
    Granules, Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Subjects received a single dose of LUM/IVA tablet or granule formulation in the fed or fasted state on Day 1 in treatment period 1, 2, 3 and 4 as per the sequence.

    Arm title
    Sequence 4
    Arm description
    Subjects received LUM/IVA Dose 1 granule formulation in fasted state in treatment period 1, then LUM/IVA Dose 2 granule formulation in fed state in treatment period 2, then LUM/IVA Dose 1 tablet formulation in fed state in treatment period 3, and then LUM/IVA Dose 1 granule formulation in fed state in treatment period 4. A washout period of at least 10 days occurred between each dosing occasion.
    Arm type
    Experimental

    Investigational medicinal product name
    LUM/IVA
    Investigational medicinal product code
    VX-809/ VX-770
    Other name
    Lumacaftor/Ivacaftor fixed dose combination
    Pharmaceutical forms
    Granules, Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Subjects received a single dose of LUM/IVA tablet or granule formulation in the fed or fasted state on Day 1 in treatment period 1, 2, 3 and 4 as per the sequence.

    Number of subjects in period 1
    Sequence 1 Sequence 2 Sequence 3 Sequence 4
    Started
    4
    4
    4
    4
    Completed
    4
    4
    4
    4

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Sequence 1
    Reporting group description
    Subjects received LUM/IVA Dose 1 tablet formulation in fed state in treatment period 1, then LUM/IVA Dose 1 granule formulation in fasted state in treatment period 2, then LUM/IVA Dose 1 granule formulation in fed state in treatment period 3, and then LUM/IVA Dose 2 granule formulation in fed state in treatment period 4. A washout period of at least 10 days occurred between each dosing occasion.

    Reporting group title
    Sequence 2
    Reporting group description
    Subjects received LUM/IVA Dose 1 granule formulation in fed state in treatment period 1, then LUM/IVA Dose 1 tablet formulation in fed state in treatment period 2, then LUM/IVA Dose 2 granule formulation in fed state in treatment period 3, and then LUM/IVA Dose 1 granule formulation in fasted state in treatment period 4. A washout period of at least 10 days occurred between each dosing occasion.

    Reporting group title
    Sequence 3
    Reporting group description
    Subjects received LUM/IVA Dose 2 granule formulation in fed state in treatment period 1, then LUM/IVA Dose 1 granule formulation in fed state in treatment period 2, then LUM/IVA Dose 1 granule formulation in fasted state in treatment period 3, and then LUM/IVA Dose 1 tablet formulation in fed state in treatment period 4. A washout period of at least 10 days occurred between each dosing occasion.

    Reporting group title
    Sequence 4
    Reporting group description
    Subjects received LUM/IVA Dose 1 granule formulation in fasted state in treatment period 1, then LUM/IVA Dose 2 granule formulation in fed state in treatment period 2, then LUM/IVA Dose 1 tablet formulation in fed state in treatment period 3, and then LUM/IVA Dose 1 granule formulation in fed state in treatment period 4. A washout period of at least 10 days occurred between each dosing occasion.

    Reporting group values
    Sequence 1 Sequence 2 Sequence 3 Sequence 4 Total
    Number of subjects
    4 4 4 4 16
    Age categorical
    Units: Subjects
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    30.8 ± 4.72 36.0 ± 9.87 37.0 ± 11.17 34.0 ± 16.21 -
    Gender categorical
    Units: Subjects
        Female
    2 2 3 3 10
        Male
    2 2 1 1 6

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Sequence 1
    Reporting group description
    Subjects received LUM/IVA Dose 1 tablet formulation in fed state in treatment period 1, then LUM/IVA Dose 1 granule formulation in fasted state in treatment period 2, then LUM/IVA Dose 1 granule formulation in fed state in treatment period 3, and then LUM/IVA Dose 2 granule formulation in fed state in treatment period 4. A washout period of at least 10 days occurred between each dosing occasion.

    Reporting group title
    Sequence 2
    Reporting group description
    Subjects received LUM/IVA Dose 1 granule formulation in fed state in treatment period 1, then LUM/IVA Dose 1 tablet formulation in fed state in treatment period 2, then LUM/IVA Dose 2 granule formulation in fed state in treatment period 3, and then LUM/IVA Dose 1 granule formulation in fasted state in treatment period 4. A washout period of at least 10 days occurred between each dosing occasion.

    Reporting group title
    Sequence 3
    Reporting group description
    Subjects received LUM/IVA Dose 2 granule formulation in fed state in treatment period 1, then LUM/IVA Dose 1 granule formulation in fed state in treatment period 2, then LUM/IVA Dose 1 granule formulation in fasted state in treatment period 3, and then LUM/IVA Dose 1 tablet formulation in fed state in treatment period 4. A washout period of at least 10 days occurred between each dosing occasion.

    Reporting group title
    Sequence 4
    Reporting group description
    Subjects received LUM/IVA Dose 1 granule formulation in fasted state in treatment period 1, then LUM/IVA Dose 2 granule formulation in fed state in treatment period 2, then LUM/IVA Dose 1 tablet formulation in fed state in treatment period 3, and then LUM/IVA Dose 1 granule formulation in fed state in treatment period 4. A washout period of at least 10 days occurred between each dosing occasion.

    Subject analysis set title
    Treatment A: LUM/IVA Dose 1 Tablet (Fed)
    Subject analysis set type
    Safety analysis
    Subject analysis set description
    All subjects who received LUM/IVA Dose 1 tablet formulation in fed state.

    Subject analysis set title
    Treatment B: LUM/IVA Dose 1 Granule (Fasted)
    Subject analysis set type
    Safety analysis
    Subject analysis set description
    All Subjects who received LUM/IVA Dose 1 granule formulation in fasted state.

    Subject analysis set title
    Treatment B: LUM/IVA Dose 1 Granule (Fed)
    Subject analysis set type
    Safety analysis
    Subject analysis set description
    All Subjects who received LUM/IVA Dose 1 granule formulation in fed state.

    Subject analysis set title
    Treatment C: LUM/IVA Dose 2 Granule (Fed)
    Subject analysis set type
    Safety analysis
    Subject analysis set description
    All Subjects who received LUM/IVA Dose 2 granule formulation in fed state.

    Primary: Maximum Observed Plasma Concentration (Cmax) of LUM and IVA

    Close Top of page
    End point title
    Maximum Observed Plasma Concentration (Cmax) of LUM and IVA [1]
    End point description
    End point type
    Primary
    End point timeframe
    Day 1 up to Day 6 for each treatment period
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: Only descriptive statistics were planned. No statistical comparisons were planned for the primary pharmacokinetic (PK) endpoint. PK set included participants who received at least 1 dose of study drug and for whom the primary PK data were considered to be sufficient and interpretable. Here “Number Analyzed” signifies those participants who were evaluable for this outcome measure in the specified treatment period.
    End point values
    Treatment A: LUM/IVA Dose 1 Tablet (Fed) Treatment B: LUM/IVA Dose 1 Granule (Fasted) Treatment B: LUM/IVA Dose 1 Granule (Fed) Treatment C: LUM/IVA Dose 2 Granule (Fed)
    Number of subjects analysed
    16
    15
    16
    15
    Units: nanogram per milliliter (ng/mL)
    arithmetic mean (standard deviation)
        LUM
    5590 ± 1150
    3060 ± 1020
    4460 ± 541
    7010 ± 1370
        IVA
    643 ± 201
    301 ± 142
    531 ± 111
    837 ± 178
    No statistical analyses for this end point

    Primary: Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity [AUC(0 - inf)] of LUM and IVA

    Close Top of page
    End point title
    Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity [AUC(0 - inf)] of LUM and IVA [2]
    End point description
    End point type
    Primary
    End point timeframe
    Day 1 up to Day 6 for each treatment period
    Notes
    [2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: Only descriptive statistics were planned. No statistical comparisons were planned for the primary PK endpoint. PK set included participants who received at least 1 dose of study drug and for whom the primary PK data were considered to be sufficient and interpretable. Here “Number Analyzed” signifies those participants who were evaluable for this outcome measure in the specified treatment period.
    End point values
    Treatment A: LUM/IVA Dose 1 Tablet (Fed) Treatment B: LUM/IVA Dose 1 Granule (Fasted) Treatment B: LUM/IVA Dose 1 Granule (Fed) Treatment C: LUM/IVA Dose 2 Granule (Fed)
    Number of subjects analysed
    16
    15
    16
    15
    Units: Hours*nanogram per milliliter (h*ng/mL)
    arithmetic mean (standard deviation)
        LUM
    133000 ± 35100
    105000 ± 24600
    118000 ± 22400
    184000 ± 38800
        IVA
    7400 ± 2590
    4070 ± 1560
    7160 ± 1880
    11100 ± 2840
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    From first dose of study drug up to 10 days after last dose of study drug in treatment period 4
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    18.1
    Reporting groups
    Reporting group title
    Treatment A: LUM/IVA Dose 1 Tablet (Fed)
    Reporting group description
    All subjects who received LUM/IVA Dose 1 tablet formulation in fed state.

    Reporting group title
    Treatment B: LUM/IVA Dose 1 Granule (Fasted)
    Reporting group description
    All Subjects who received LUM/IVA Dose 1 granule formulation in fasted state.

    Reporting group title
    Treatment B: LUM/IVA Dose 1 Granule (Fed)
    Reporting group description
    All Subjects who received LUM/IVA Dose 1 granule formulation in fed state.

    Reporting group title
    Treatment C: LUM/IVA Dose 2 Granule (Fed)
    Reporting group description
    All Subjects who received LUM/IVA Dose 2 granule formulation in fed state.

    Serious adverse events
    Treatment A: LUM/IVA Dose 1 Tablet (Fed) Treatment B: LUM/IVA Dose 1 Granule (Fasted) Treatment B: LUM/IVA Dose 1 Granule (Fed) Treatment C: LUM/IVA Dose 2 Granule (Fed)
    Total subjects affected by serious adverse events
         subjects affected / exposed
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    1 / 16 (6.25%)
    0 / 15 (0.00%)
         number of deaths (all causes)
    0
    0
    0
    0
         number of deaths resulting from adverse events
    Injury, poisoning and procedural complications
    Gun shot wound
         subjects affected / exposed
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    1 / 16 (6.25%)
    0 / 15 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    Treatment A: LUM/IVA Dose 1 Tablet (Fed) Treatment B: LUM/IVA Dose 1 Granule (Fasted) Treatment B: LUM/IVA Dose 1 Granule (Fed) Treatment C: LUM/IVA Dose 2 Granule (Fed)
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    5 / 16 (31.25%)
    2 / 15 (13.33%)
    3 / 16 (18.75%)
    6 / 15 (40.00%)
    Injury, poisoning and procedural complications
    Arthropod bite
         subjects affected / exposed
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    1 / 16 (6.25%)
    0 / 15 (0.00%)
         occurrences all number
    0
    0
    1
    0
    Nervous system disorders
    Headache
         subjects affected / exposed
    3 / 16 (18.75%)
    2 / 15 (13.33%)
    1 / 16 (6.25%)
    2 / 15 (13.33%)
         occurrences all number
    3
    2
    1
    2
    Eye disorders
    Dry eye
         subjects affected / exposed
    1 / 16 (6.25%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
         occurrences all number
    1
    0
    0
    0
    Gastrointestinal disorders
    Nausea
         subjects affected / exposed
    1 / 16 (6.25%)
    1 / 15 (6.67%)
    2 / 16 (12.50%)
    0 / 15 (0.00%)
         occurrences all number
    1
    1
    2
    0
    Dyspepsia
         subjects affected / exposed
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    1 / 15 (6.67%)
         occurrences all number
    0
    0
    0
    1
    Toothache
         subjects affected / exposed
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    1 / 15 (6.67%)
         occurrences all number
    0
    0
    0
    1
    Skin and subcutaneous tissue disorders
    Eczema
         subjects affected / exposed
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    2 / 15 (13.33%)
         occurrences all number
    0
    0
    0
    2
    Erythema
         subjects affected / exposed
    0 / 16 (0.00%)
    0 / 15 (0.00%)
    1 / 16 (6.25%)
    0 / 15 (0.00%)
         occurrences all number
    0
    0
    1
    0
    Infections and infestations
    Folliculitis
         subjects affected / exposed
    1 / 16 (6.25%)
    0 / 15 (0.00%)
    0 / 16 (0.00%)
    0 / 15 (0.00%)
         occurrences all number
    1
    0
    0
    0

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? No

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    As of 1.2.2020, the UK is no longer an EU Member State. However, EU law still applies to the UK during the transition period
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2020 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA